John W. V Umstead
CIK 1967910 · Chief Financial Officer · last filed 2024-09-18
John W. V Umstead is a Chief Financial Officer who has filed 9 SEC Form 4 insider transactions across 1 company since 2023. The most recent filing, for GTHX, was dated Sep 18, 2024. Across all open-market trades the lifetime net is −$62.4K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
9
-$62.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| G1 Therapeutics, Inc. (GTHX) Delisted | Chief Financial Officer | 19,331 | $7.15 | $138.2K | -$62.4K | 9 | 2024-09-18 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-18 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | −187,718 | $0 | EDGAR |
| 2024-07-08 | G1 Therapeutics, Inc. (GTHX) Delisted | Sell (S) | −527 | -$1.3K | EDGAR |
| 2024-07-03 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2024-05-15 | G1 Therapeutics, Inc. (GTHX) Delisted | Sell (S) | −8,151 | -$39.0K | EDGAR |
| 2024-03-22 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +37,500 | $0 | EDGAR |
| 2024-03-20 | G1 Therapeutics, Inc. (GTHX) Delisted | Sell (S) | −6,547 | -$19.8K | EDGAR |
| 2024-01-08 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | +36,557 | -$2.3K | EDGAR |
| 2023-05-12 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2023-03-17 | G1 Therapeutics, Inc. (GTHX) Delisted | Grant (A) | +50,000 | $0 | EDGAR |